PERL study will explore the potential of allopurinol to delay or halt kidney disease in people with type 1 diabetes. As we near the end of March, National Kidney Month, we find ourselves at the beginning stages of an exciting new clinical trial that could lead to better health for people with type 1 diabetes […]
Updated criteria could open new possibilities for intervention before symptoms appear JDRF is leading a pertinent discussion in the diabetes field about what defines a diagnosis of type 1 diabetes (T1D). At the 14th Annual Rachmiel Levine Diabetes and Obesity Symposium today, Richard Insel, M.D., JDRF’s chief scientific officer, reviewed evidence supporting the need to […]
JDRF has a plan for creating a world without type 1 diabetes (T1D) that focuses on driving promising therapies through the R&D pipeline and into the hands of individuals with T1D. A critical step in progress along the pipeline is known as the translational research phase. The goal of translational research is to move research […]
Although scientists are still working to determine what causes type 1 diabetes (T1D), research has given us insights into the disease process – knowledge that may eventually lead to potential therapies. One idea that has been explored over the past several years is that of beta cell stress and its connection to T1D, and a […]
We’re the plan to change the future type. JDRF research focuses on key therapies that hold significant promise in turning Type One into Type None, including: artificial pancreas, encapsulation, smart insulin, restoration, and prevention.
A new JDRF-funded study will evaluate whether metformin—a drug commonly used to treat type 2 diabetes (T2D)—combined with standard insulin therapy could safely improve blood-glucose control in overweight children and adolescents with type 1 diabetes (T1D). For more than 50 years, metformin has proven safe and effective in helping to control blood-glucose levels in people […]
A clinical study published in PNAS provides further proof-of-concept that beta cell encapsulation holds real promise for making islet implantation a viable therapy for people with type 1 diabetes (T1D).
JDRF-funded researchers across the globe are currently testing artificial pancreas systems. Some clinical trials are inpatient, in which participants stay overnight or for a few days in a hospital or research clinic, while others take place in an outpatient setting. In both cases, a medical team carefully monitors the daily life of each trial volunteer […]
Stephen D. Miller, Ph.D., is the Judy Gugenheim Research Professor of Microbiology–Immunology at Northwestern University Feinberg School of Medicine. Dr. Miller has spent 32 years as a faculty member at Northwestern, where his research focuses on understanding the mechanisms underlying the pathogenesis and immunoregulation of autoimmune diseases, allergic disease, and rejection of tissue and organ […]
Welcome to our final daily summary of type 1 diabetes (T1D) research highlights from the ADA’s 73rd Scientific Sessions! Each night, we have been posting summaries of notable sessions and presentations. Below are two relevant sessions from Monday, June 24: From Mice to Men and Back in Diabetic Kidney Disease Diabetic kidney disease remains one of […]